Turn Therapeutics provides pipeline update; GX-03 Phase 2 data expected H1 2026, appoints Martin Dewhurst to board

Turn Therapeutics Inc.

Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track; interim and topline data expected first half of 2026.
Martin Dewhurst (30+ year McKinsey M&A veteran) appointed to Board of Directors.
Vaccine pipeline expanded to include intranasal influenza candidate; in-vivo/vitro studies start Q1 2026.
Commercial partnership with Medline expected to generate near-term revenue in 2026 in wound care.
Strengthened balance sheet via share purchase agreement extends cash runway into late 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.